Collegium Pharmaceutical Inc. (COLL) Trading Down 5.1%
Collegium Pharmaceutical Inc. (NASDAQ:COLL)’s share price dropped 5.1% during mid-day trading on Tuesday . The company traded as low as $11.89 and last traded at $12.15, with a volume of 103,519 shares. The stock had previously closed at $12.80.
COLL has been the topic of a number of research reports. Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, July 6th. Needham & Company LLC restated a “buy” rating and issued a $30.00 price target (up from $28.00) on shares of Collegium Pharmaceutical in a research note on Thursday, May 26th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $26.00 target price on shares of Collegium Pharmaceutical in a research report on Thursday, May 26th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $29.25.
The company’s market cap is $285.15 million. The firm’s 50-day moving average is $14.01 and its 200-day moving average is $16.91.
Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.08. Analysts anticipate that Collegium Pharmaceutical Inc. will post ($3.25) EPS for the current fiscal year.
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.